ArticleTranslational cancer research2026
Combining Napsin A expression with circulating tumor cell counts for enhanced identification of pulmonary adenocarcinoma in ground-glass nodules.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating tumor cells (CTCs) have shown potential for early lung cancer diagnosis, but their sensitivity and isolation yield are currently limited. Napsin A is a sensitive and specific marker for adenocarcinoma diagnosis. Therefore, combining CTC detection with Napsin A expression analysis may provide an accurate method for identifying pulmonary adenocarcinoma in ground-glass nodules (GGNs), which could significantly improve patient survival rates. This study aims to evaluate the diagnostic value of detecting Napsin A‑positive CTCs for identifying pulmonary adenocarcinoma among patients with GGNs. Methods: Peripheral blood samples were collected from 91 patients who had been diagnosed with GGNs. CTCs were captured using an efficient nano-enrichment method, and Napsin A expression was detected through immunofluorescent labeling. The diagnostic value of these metrics for pulmonary adenocarcinoma in GGNs was evaluated using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC). Results: Our findings demonstrate that the number of CTCs in patients in the malignant group was significantly higher than that in the benign group (P<0.001). ROC analysis reveals an AUC of 0.627 for CTC detection alone, with a sensitivity of 63.64% and specificity of 72.46%. However, when CTC counts were combined with Napsin A-positive expression (Napsin A Conclusions: The combination of CTC counting and Napsin A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.